Loading…
Loading…
CWA Asset Management Group LLC grew its stake in Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) by 71.7% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 498,643 shares of the biotechnology company's stock after purchasing an additional 208,277 shares during the
BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases, today announced that its Board of Directors appointed Chief Commercial Officer Tammi Gaskins as Chief Executive Officer and a member of the Board of Directors, effective January 1, 2027. On that date Chief Executive Officer Tom McCourt will retire from his current role and will remai.
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the seven research firms that are presently covering the firm, MarketBeat.com reports. Four investment analysts have rated the stock with a hold rating, two have issued a buy rating and one has issued a strong buy rating on
IRWD's Linzess demand remains strong, with a recent pediatric label expansion and pricing changes poised to support third-quarter 2026 growth.
Ironwood Pharmaceuticals is rated Buy, but the investment thesis hinges on apraglutide, not Linzess, due to looming generic competition. IRWD's Linzess cash flow is largely committed to debt and taxes, with generics expected by 2029 and Medicare price cuts impacting margins. Apraglutide's value depends on successful STARS-2 trial results and timely approval, with peak sales modeled conservatively at $456 million.
Precigen's Papzimeos and Ironwood's Linzess are driving growth, but competition, pipeline progress and single-product reliance shape each biotech's outlook.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
INDV, IRWD, RLMD, LRMR and CRDL could offer significant upside as biotech sentiment improves, backed by catalysts and differentiated pipelines.